Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries

European Journal of Pharmacology

Volumn 619, Issue 1-3, 2009, Pages 61-67

  Chan, Kayi Y ^a   de Vries, René ^a   Leijten, Frank P J ^a   Pfannkuche, Hans Juergen ^b   van den Bogaerdt, Antoon J ^a   Danser, Alexander H J ^a   MaassenVanDenBrink, Antoinette ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

5 HT1B receptor; Human coronary artery; Sumatriptan; Tegaserod

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; MESSENGER RNA; SEROTONIN 1B RECEPTOR; SEROTONIN 4 AGONIST; SUMATRIPTAN; TEGASEROD;

ARTERY CONSTRICTION; ARTICLE; BINDING AFFINITY; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN TISSUE; IRRITABLE COLON; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RISK FACTOR; VASCULAR ENDOTHELIUM; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADOLESCENT; ADULT; BENZAMIDES; CORONARY VESSELS; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MUSCLE CONTRACTION; PYRIDINES; RECEPTORS, SEROTONIN, 5-HT4; RNA, MESSENGER; SEROTONIN AGONISTS; SUMATRIPTAN; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 69749097048     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.07.010     Document Type: Article

References (30)

1. 4 receptor partial agonist with promotile activity. Clin. Pharmacokinet. 41 (2002) 1021-1042
2. Appel-Dingemanse S., Hirschberg Y., Osborne S., Pommier F., and McLeod J. Multiple-dose pharmacokinetics confirm no accumulation and dose proportionality of the novel promotile drug tegaserod (HTF 919). Eur. J. Clin. Pharmacol. 56 (2001) 889-891
3. Bach T., Syversveen T., Kvingedal A.M., Krobert K.A., Brattelid T., Kaumann A.J., and Levy F.O. 5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle. Naunyn Schmiedebergs Arch. Pharmacol. 363 (2001) 146-160
4. Batenburg W.W., van Esch J.H., Garrelds I.M., Jorde U., Lamers J.M., Dekkers D.H., Walther T., Kellett E., Milligan G., van Kats J.P., and Danser A.H. Carvedilol-induced antagonism of angiotensin II: a matter of alpha1-adrenoceptor blockade. J. Hypertens. 24 (2006) 1355-1363
5. 2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 143 (2004) 549-560
6. Beattie D.T., Zamora F., Pulido-Rios T., and Humphrey P.P.A. Tegaserod, But Not TD-5108, Has Effect in Porcine and Canine Isolated Coronary Arteries (2008), British Pharmacologal Society
7. Busti A.J., Murillo Jr. J.R., and Cryer B. Tegaserod-induced myocardial infarction: case report and hypothesis. Pharmacotherapy 24 (2004) 526-531
8. Camilleri M. Review article: tegaserod. Aliment. Pharmacol. Ther. 15 (2001) 277-289
9. 4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 20 (2008) 99-112
10. DeLean A., Munson P.J., and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235 (1978) E97-102
11. Gershon M.D. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment. Pharmacol. Ther. 20 Suppl 7 (2004) 3-14
12. Gupta S., Mehrotra S., Villalón C.M., Garrelds I.M., de Vries R., van Kats J.P., Sharma H.S., Saxena P.R., and MaassenVanDenBrink A. Characterisation of CGRP receptors in human and porcine isolated coronary arteries: evidence for CGRP receptor heterogeneity. Eur. J. Pharmacol. 530 (2006) 107-116
13. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71 (2002) 533-554
14. 2 receptor subtypes in human coronary arteries. Cardiovasc. Res. 41 (1999) 267-274
15. Kaumann A.J., Sanders L., Brown A.M., Murray K.J., and Brown M.J. A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol. 100 (1990) 879-885
16. 1B-receptors. Br. J. Clin. Pharmacol. 46 (1998) 577-582
17. MaassenVanDenBrink A., Bax W.A., Ferrari M.D., Zijlstra F.J., Bos E., and Saxena P.R. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br. J. Pharmacol. 119 (1996) 855-862
18. MaassenVanDenBrink A., Reekers M., Bax W.A., Ferrari M.D., and Saxena P.R. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98 (1998) 25-30
19. MaassenVanDenBrink A., Bax W.A., Ramrattan N.N., Ferrari M.D., and Saxena P.R. Human isolated coronary artery contraction to sumatriptan: a post hoc analysis. Cephalalgia 19 (1999) 651-654
20. 1B/1D receptor antagonist GR55562. Pharmacol. Toxicol. 86 (2000) 287-290
21. MaassenVanDenBrink A., van den Broek R.W.M., de Vries R., Bogers A.J.J.C., Avezaat C.J.J., and Saxena P.R. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 55 (2000) 1524-1530
22. MaassenVanDenBrink A., van den Broek R.W.M., de Vries R., Upton N., Parsons A.A., and Saxena P.R. The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 20 (2000) 538-545
23. 1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation 87 (1993) 401-405
24. Mulvany M.J., and Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ. Res. 41 (1977) 19-26
25. Pasricha P.J. Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders. Gastroenterology 132 (2007) 2287-2290
26. Pfannkuche H.J., and Dennis E. Tegaserod-induced myocardial infarction: case report and hypothesis-an alternative viewpoint. Pharmacotherapy 24 (2004) 1649-1650 discussion 1650-1641
27. Ullmer C., Schmuck K., Kalkman H.O., and Lubbert H. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett. 370 (1995) 215-221
28. van den Broek R.W., Bhalla P., VanDenBrink A.M., de Vries R., Sharma H.S., and Saxena P.R. Characterization of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HT(1B) and 5-HT(1D) receptor antagonists and in situ hybridization. Cephalalgia 22 (2002) 83-93
29. Villalón C.M., and Centurión D. Cardiovascular responses produced by 5-hydroxytriptamine: a pharmacological update on the receptors/mechanisms involved and therapeutic implications. Naunyn Schmiedeberg's Arch. Pharmacol. 376 (2007) 45-63
30. Weber E., Hamel C.T., Bernhard M., and Pfannkuche H.-J. Tegaserod has no potential for vasoconstriction or impairment of vasodilatation in isolated human and non-human primate mesenteric arteries. Gastroenterology 130 (2006) A-489